Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals announced the exercise of warrants for 67,371 new ordinary shares, generating £235,799 in subscription monies. The new shares will be admitted to trading on the LSE, increasing the total number of issued shares to 5,361,267, which shareholders should use for determining changes in share capital interests.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 82,481
Technical Sentiment Signal: Buy
Current Market Cap: £33.85M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.